OR WAIT null SECS
September 29, 2023
Biologics formulation comes with a unique set of challenges, which can be overcome through innovative strategies and good partnerships.
September 15, 2023
Despite its success, clinical and logistical roadblocks to mRNA cancer vaccine development remain.
September 02, 2023
Nanoparticles offer the potential for a safer, more effective method of drug delivery to the patient.
June 14, 2023
When one is using continuous hot-melt extrusion to enhance solubility, process control is essential.
May 25, 2023
Hanns-Christian Mahler and Andrea Allmendinger from ten23 health will discuss some key aspects of biologic drug development and manufacturing.
May 17, 2023
This deal would help the companies merge to work on future projects and conduct research together.
May 04, 2023
Presspart will still be responsible for the manufacturing of the Sunriser device.
March 23, 2023
Advancements in therapeutic modalities are necessitating change in drug delivery to help negate some of the expense of development and manufacturing.
March 17, 2023
Polyplus’ LipidBrick is designed to expand the scope of lipid nanoparticle formulation usage in mRNA therapeutics and vaccine development.
Under a technology licensing agreement with Bhami Research Laboratory, Catalent intends to develop formulations that will allow for the delivery of high-concentration biologics subcutaneously.